GLP Peptides
For customers comparing appetite, metabolic, and weight-management research peptides before opening a specific vial guide.
How to Think About This Family
- Semaglutide is the established GLP-1 reference point.
- Tirzepatide adds GIP activity and is usually treated as the stronger next step.
- Retatrutide is the more experimental triple-pathway option, with less settled long-term evidence.
- Cagrilintide and AOD-9604 fit adjacent metabolic research questions rather than the classic GLP-only lane.
Practical Caveat
Semaglutide and tirzepatide have FDA-approved prescription versions, but research-use products are not the same as prescribed medication. Retatrutide, cagrilintide, and AOD-style products need extra caution because the customer-facing evidence picture is less mature.
Open the Exact Product Guide
Semaglutide 5mg Established GLP-1 benchmark. Semaglutide 30mg Higher-size semaglutide guide. Tirzepatide 10mg Dual GLP-1/GIP starting point. Tirzepatide 20mg Same family, larger vial. Tirzepatide 30mg Concentrated tirzepatide guide. Tirzepatide 60mg Most concentrated tirzepatide guide. Retatrutide 10mg Investigational triple-pathway option. Retatrutide 20mg Same retatrutide concentration approach. Retatrutide 30mg Larger retatrutide vial guide. Retatrutide 60mg Concentrated retatrutide guide. Cagrilintide 10mg Amylin-pathway metabolic research. AOD-9604 5mg Adjacent fat-metabolism research topic.